

## Clinical Policy: Pyrimethamine (Daraprim)

Reference Number: ERX.NPA.44

Effective Date: 12.01.15

Last Review Date: 08.21

Line of Business: Commercial, Medicaid

[Revision Log](#)

See **Important Reminder** at the end of this policy for important regulatory and legal information.

### Description

Pyrimethamine (Daraprim<sup>®</sup>) is a folic acid antagonist.

### FDA Approved Indication(s)

Daraprim is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide.

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

*Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.*

It is the policy of health plans affiliated with Envolve Pharmacy Solutions<sup>™</sup> that Daraprim is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Initial Therapy for Toxoplasmosis Infection – Active Disease (must meet all):

1. Diagnosis of toxoplasmosis;
2. Prescribed by or in consultation with an infectious disease or HIV specialist;
3. Member meets one of the following (a or b):
  - a. Age < 18 years;
  - b. Failure of  $\geq 10$  days, or radiological deterioration within 7 days, of trimethoprim/sulfamethoxazole (TMP/SMX), unless contraindicated or clinically significant adverse effects are experienced;
4. Daraprim is prescribed with sulfadiazine or clindamycin, and leucovorin;
5. If request is for the brand product, member must use the generic product, unless contraindicated or clinically significant adverse effects are experienced;
6. Request meets one of the following (a, b, or c):
  - a. Immunocompromised member: Dose does not exceed an initial loading dose of 200 mg, followed by  $\leq 75$  mg per day for treatment duration;
  - b. Immunocompetent member: Dose does not exceed an initial loading dose of 100 mg, followed by  $\leq 50$  mg per day for treatment duration;
  - c. Dose is supported by practice guidelines or peer-reviewed literature for the relevant use (*prescriber must submit supporting evidence*).

##### Approval duration:

**Congenital toxoplasmosis in newborns – 12 months**

**All other requests – Duration of request or 8 weeks (whichever is less)**

##### B. Primary Prophylaxis for Toxoplasmosis – Preventing 1<sup>st</sup> Episode (off-label) (must meet all):

1. Diagnosis of HIV infection;
2. Prescribed by or in consultation with an infectious disease or HIV specialist;
3. Request is for prevention for toxoplasmosis;
4. CD4 count < 100 cells/mm<sup>3</sup>;
5. Seropositive for *Toxoplasma gondii* IgG;

6. Member is contraindicated or has experienced clinically significant adverse effects to TMP/SMX;
7. Daraprim is prescribed with leucovorin and dapsone;
8. If request is for the brand product, member must use the generic product, unless contraindicated or clinically significant adverse effects are experienced;
9. Dose does not exceed 75 mg per week.

**Approval duration: 6 months**

**C. Other diagnoses/indications**

1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

**II. Continued Therapy**

**A. Chronic Maintenance – Following Initial Therapy for Active Disease (off-label)** (must meet all):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
2. Member is HIV-infected with CD4 count  $\leq 200$  cells/mm<sup>3</sup> at any time in the previous 6 months;
3. Adherence to antiretroviral therapy as evidenced by pharmacy claims history or office notes;
4. If request is for the brand product, member must use the generic product, unless contraindicated or clinically significant adverse effects are experienced;
5. Request meets one of the following (a or b):
  - a. Dose does not exceed 50 mg per day;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant use (*prescriber must submit supporting evidence*).

**Approval duration: 6 months**

**B. Primary Prophylaxis for Toxoplasmosis – Preventing 1<sup>st</sup> Episode (off-label)** (must meet all):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
2. Member is HIV-infected with CD4 count  $\leq 200$  cells/mm<sup>3</sup> at any time in the previous 3 months;
3. Adherence to antiretroviral therapy as evidenced by pharmacy claims history or office notes;
4. If request is for the brand product, member must use the generic product, unless contraindicated or clinically significant adverse effects are experienced;
5. Dose does not exceed 75 mg per week.

**Approval duration: 3 months**

**C. Other diagnoses/indications** (must meet 1 or 2):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.

**Approval duration: Duration of request or 12 months (whichever is less);** or

2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents;
- B.** Malaria.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

CDC: Centers for Disease Control and Prevention

FDA: Food and Drug Administration

HHS: Department of Health and Human Services

HIV: human immunodeficiency virus

TMP/SMX: trimethoprim/sulfamethoxazole

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria.*

*The drugs listed here may not be a formulary agent and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
trimethoprim/sulfamethoxazole (Bactrim®, Bactrim® DS)*	Treatment: TMP 5 mg/kg and SMX 25 mg/kg IV or PO BID  Primary prophylaxis: 1 DS PO QD (preferred) or 1 DS TIW or 1 SS QD  Chronic maintenance: 1 DS PO QD or BID	See regimen

*Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.*

*\*Off-label uses; dosing recommendations per HHS guidelines*

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): documented megaloblastic anemia due to folate deficiency, known hypersensitivity to pyrimethamine or to any component of the formulation
- Boxed warning(s): none reported

*Appendix D: General Information*

- On June 21, 2017, Daraprim’s FDA labeling was updated to exclude the previously approved indications for treatment and chemoprophylaxis of malaria. These uses are not recommended per the CDC malaria treatment guidelines due to prevalent worldwide resistance to pyrimethamine.
- For the treatment of toxoplasmosis, higher doses than what is recommended by the FDA, HHS, and CDC may be required for severe cases or cases affecting sequestered sites such as chorioretinitis.

**V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
Treatment of toxoplasmosis	Administered PO in combination with a sulfonamide ± leucovorin; recommended dosing regimen varies per guideline referenced:  <u>FDA labeling</u> Adults: 50-75 mg daily for 1-3 weeks depending on the response of the patient and tolerance to therapy, followed by one-half of the initial dose continued for an additional 4 to 5 weeks Pediatrics: 1 mg/kg/day divided into 2 equal daily doses for 2-4 days, followed by one-half of the initial dose continued for approximately 1 month  <u>HHS guidelines [HIV-infected patients]</u> Initial loading dose of 200 mg, followed by 50 mg/day (if body weight ≤ 60 kg) or 75 mg/day (if body weight > 60 kg) for the remainder of treatment duration  <u>CDC guidelines</u> [ocular toxoplasmosis]	300 mg/day

Indication	Dosing Regimen	Maximum Dose
	Adult: Initial loading dose of 100 mg, followed by 25-50 mg/day for the remainder of treatment duration (usually 4-6 weeks) Pediatric: Initial loading dose of 2 mg/kg, followed by 1 mg/kg/day for the remainder of treatment duration (usually 4-6 weeks) [congenital toxoplasmosis] Newborns: 2 mg/kg per day, divided twice per day for the first 2 days; then from day 3 to 2 months (or 6 months if symptomatic) 1 mg/kg per day, every day; then 1 mg/kg per day 3 times per week for a total of 12 months	
Primary prophylaxis of toxoplasmosis*	50-75 mg/week PO in combination with a sulfonamide  Recommended treatment regimen is Daraprim 50 mg per week plus dapsone 50 mg once daily plus leucovorin 25 mg per week or Daraprim 75 mg plus dapsone 200 mg plus leucovorin 25 mg weekly	75 mg/week
Chronic maintenance therapy (secondary prophylaxis of toxoplasmosis)*	25-50 mg/day PO in combination with a sulfonamide	50 mg/day

\*Off-label uses recommended by the HHS guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents

## VI. Product Availability

Tablet: 25 mg

## VII. References

1. Daraprim Prescribing Information. Raleigh, NC: Salix Pharmaceuticals, Inc.; August 2017. Available at: [www.daraprimdirect.com](http://www.daraprimdirect.com). Accessed March 18, 2021.
2. Panel on Opportunistic Infections in HIV-infected Adults and Adolescents. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents - Toxoplasma gondii encephalitis: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Department of Health and Human Services. Available at: <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/toxoplasma-gondii-encephalitis>. Updated July 25, 2017. Accessed March 18, 2021.
3. Global Health - Division of Parasitic Diseases and Malaria. Treatment of malaria: guidelines for clinicians (United States). Centers for Disease Control and Prevention. [http://www.cdc.gov/malaria/diagnosis\\_treatment/treatment.html](http://www.cdc.gov/malaria/diagnosis_treatment/treatment.html). Updated November 2, 2020. Accessed March 18, 2021.
4. Sulfamethoxazole/trimethoprim. In: DRUGDEX® System [Internet database]. Greenwood Village, Colo: Thomson Micromedex. Updated periodically. Accessed April 21, 2020.
5. Torre D, Casari S, Speranza F, et al. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Antimicrob Agents Chemother. 1998; 42(6): 1346-1349.
6. Global Health - Division of Parasitic Diseases and Malaria. Resources for health professionals: toxoplasmosis. Centers for Disease Control and Prevention. Available at [http://www.cdc.gov/parasites/toxoplasmosis/health\\_professionals/index.html](http://www.cdc.gov/parasites/toxoplasmosis/health_professionals/index.html). Updated May 26, 2020. Accessed March 18, 2021.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
<ul style="list-style-type: none"> <li>- Converted to new template.</li> <li>- Daraprim is no longer indicated for malaria as of 06/2017. Updated policy to reflect this.</li> <li>- Initial therapy for active disease: Modified TMP/SMX trial duration to be at least 10 days (vs range of 10-14 days) for failure (i.e., lack of clinical improvement) and within 7 days for radiological deterioration. Modified approval duration to up to 8 weeks for all members (vs 6 weeks for immunocompromised and 4 weeks for immunocompetent) per FDA labeling as well as literature review that indicates treatment duration may take longer than 6 and 4 weeks for these populations.</li> <li>- Primary prophylaxis: For initial criteria, modified to allow coverage for members who have experienced clinically significant adverse effects (vs only contraindications) to TMP/SMX. For continued criteria, added requirement of adherence to ART. Corrected CD4 requirement from &lt; 200 cells/mm<sup>3</sup> to ≤ 200 cells/mm<sup>3</sup> per guidelines.</li> <li>- Chronic maintenance therapy: For continued criteria, corrected CD4 requirement from &lt; 200 cells/mm<sup>3</sup> to ≤ 200 cells/mm<sup>3</sup> per guidelines. Removed requirement for documentation of positive response to therapy as therapy should be continued so long as CD4 ≤ 200 cells/mm<sup>3</sup>.</li> </ul>	06.17	08.17
3Q 2018 annual review: no significant changes; HIV specialist added as prescriber option; removed recommended regimens from continued criteria and moved to Section V Dosage and Administration; references reviewed and updated.	04.02.18	08.18
3Q 2019 annual review: no significant changes; references reviewed and updated.	04.22.19	08.19
3Q 2020 annual review: added requirement for use of generic products before brand product; for treatment of toxoplasmosis, added additional pathway to allow for higher dosing in unique cases per specialist feedback; references reviewed and updated.	04.20.20	08.20
3Q 2021 annual review: added initial approval duration of 12 months for treatment of congenital toxoplasmosis in newborns per CDC guidelines; revised “medical justification” to “must use” language; added requirement for use of generic to continued criteria; references reviewed and updated.	03.18.21	08.21

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2015 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.